GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » Net Margin %

ACTU (Actuate Therapeutics) Net Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Actuate Therapeutics's Net Income for the three months ended in Dec. 2024 was $-6.45 Mil. Actuate Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Actuate Therapeutics's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Actuate Therapeutics's Net Margin % or its related term are showing as below:


ACTU's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -132.46
* Ranked among companies with meaningful Net Margin % only.

Actuate Therapeutics Net Margin % Historical Data

The historical data trend for Actuate Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics Net Margin % Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Net Margin %
- - -

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Actuate Therapeutics's Net Margin %

For the Biotechnology subindustry, Actuate Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actuate Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's Net Margin % falls into.


;
;

Actuate Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Actuate Therapeutics's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-27.285/0
= %

Actuate Therapeutics's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-6.446/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actuate Therapeutics  (NAS:ACTU) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Actuate Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Actuate Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.